Lyme disease, a tick-borne illness, continues to expand its geographical reach and impact on public health. However, a promising new vaccine developed by Pfizer and Valneva is on the horizon, potentially offering a significant tool to reduce infection rates.
While its potential to curb the spread of this illness is clear, achieving widespread impact will depend on successfully navigating the federal approval process and ensuring broad acceptance and uptake among patients.
